opportun
risk
matt mindset zbh result call manag provid
guidanc gave thought pace shape recoveri new ceo
bryan hanson took advantag forum qualit rebas expect
suppli recoveri
mileston mr hanson take potenti achiev full suppli
tabl given complex scope challeng warsaw
note experi type project never go plan
manag drew distinct suppli
reacceler note former would lead latter delay
take time consist full recoveri level give confid back
sale organ custom talk gradual recoveri
rep full bag outlook forc us revisit
number moder growth expect
lower ep estim
recoveri
number new product launch partial stemless shoulder
revis cementless knee robot system unlik
see materi revenu net-net think street number
high lower number pt account gradual
recoveri higher spend even assum still like see
near term challeng think stock take time work
expect improv occur lower pt base
ep prior price target base multipl
pro-forma ep estim
quarterli annual ep usd
lower usd
return equiti ttm
link barclay live interact chart
consensu number thomson reuter
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
overweight suppli improv expect
see better top line growth benefit
market-lead portfolio stabl sale forc
new product expect growth
improv help multipl expand
leverag increas
share gain help new product
commerci cost synergi upsid valuat
weak util affect core hip knee
market share loss core market price
pressur disrupt sale forc cost
competit continu suppli issu
guidanc weaker anticip
expect revenu rang xfx
versu con also expect ep first quarter vs con
gross margin expect low end full year rang
tax rate expect rang free cash flow expect
rang
expect growth improv cours year
driven normal bill day increas suppli better commerci
execut new product launch new product launch includ
persona tibia knee persona revis knee med-tech rosa knee applic
gross margin expect rang improv lower end
rang cours year gm signific headwind
suppli challeng annual y/i year tax rate expect
benefit tax save reinvest busi aim
drive increas top line growth sg cost experi headwind
compens paid partial comp full year free cash flow
guidanc provid expect plan use
free cash flow primarili pay debt
million lowmidpointhighreport less bill dayreport softer market growth disributor order ap less elect proceduresxfx ukgross translat headwind fewer gain tax guidanc provid barclay
address current challeng plan focu qualiti remedi
effort manufactur facil warsaw indiana restor suppli import
product knee hip categori issu result
qualiti remedi non-autom warsaw north campu believ
correct strategi place note current track plan howev
resolv suppli issu may ultim take longer previous guid
previou estim full recoveri suppli
anticip could take longer expect consid prior guidanc
comment risk opportun describ new
timelin ramp market growth suppli recoveri end
still possibl note issu occur could delay plan also
made observ even suppli back take time commerci
execut follow given fact prior timelin suppli recoveri
incorrect sale hesit go offens fulli commit assur
suppli realli avail
specif note part suppli recoveri move non-autom
high-volum process contract manufactur support drive increas
volum within verif valid process necessari cant realli
acceler addit fda still need return warsaw north campu
sanction work qualiti remedi supplier commit
senior manag spend use consult support process howev
outcom ultim depend view fda
less bill day normal yeargrowthexpect improv rate fx contributionth year driven increasingn suppli level growth ex-fxenhanc commerci execut new productsorgan growthpricingmarket growthgross end improv subsequ quarterssg anorm expensecontinu invest core initi includ robot impli op headwind perform base comptax rate mfg sale mix tax initiativesdilut share guidanc provid barclay
result better expect
report result includ sale y/i
xfx vs con ep vs con knee revenu
declin xfx vs con hip sale grew xfx vs con
 sale grew xfx vs con dental sale
decreas xfx vs con spine cmf revenu
increas vs con revenu increas xfx vs
con region america revenu xfx emea
revenu xfx apac revenu xfx
revenu mm
inc growthbarclay consensusy/yxfxtot cmf mm except ep actualbarclay consensu barclay inc
inc growthbarclay dilut mm except ep actualbarclay consensu barclay inc
compani report barclay research
million except per share end dec last updat increas growth growth cash-flow ebitda profit ebit incom incom tax incom net average share ep cont increas cont op ex increas barclay zimmer biomet hold inc
matthew taylor cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli
relat specif recommend view express research report
